Followers | 4054 |
Posts | 151724 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Monday, September 25, 2023 6:32:10 PM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172891333
https://dilutiontracker.com/app/search/FEMY
Overall Risk
Low
https://finviz.com/quote.ashx?t=FEMY&p=d
Message in reply to:
Femasys (FEMY) receives FDA 510(k) clearance for FemaSeed
PR is imminent, probably Tuesday. Low float and low volume stock, trade carefully.
510(k) Number K231730
Device Name FemaSeed Intratubal Insemination
Applicant
Femasys Inc.
3950 Johns Creek CT.
Suwanee, GA 30024
Applicant Contact Christine Thomas
Correspondent
Femasys Inc.
3950 Johns Creek CT.
Suwanee, GA 30024
Correspondent Contact Christine Thomas
Regulation Number 884.6110
Classification Product Code
MQF
Date Received 06/13/2023
Decision Date 09/22/2023
Decision Substantially Equivalent (SESE)
Regulation Medical Specialty Obstetrics/Gynecology
510k Review Panel Obstetrics/Gynecology
Type Traditional
Reviewed by Third Party No
Combination Product No
![Bullish](/static/images/ih2-bull.png)
Recent FEMY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:49:26 PM
- Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/07/2024 08:01:11 PM
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative • GlobeNewswire Inc. • 05/17/2024 12:30:00 PM
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council • GlobeNewswire Inc. • 05/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 12:40:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:35:22 PM
- Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Femasys Expands Commercial Management Team with Addition of Experienced New Hires • GlobeNewswire Inc. • 05/07/2024 12:30:00 PM
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives • GlobeNewswire Inc. • 04/18/2024 12:30:00 PM
- Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape • GlobeNewswire Inc. • 03/21/2024 01:00:00 PM
- Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility • GlobeNewswire Inc. • 03/20/2024 12:15:00 PM
- Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 • GlobeNewswire Inc. • 03/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:09:27 PM
- Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:16:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:47:58 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:44:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:47:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:42:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:42:56 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/11/2023 05:15:27 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/08/2023 02:28:26 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM